Composition: Each Film Coated Tablet contains Empagliflozin 10 mg, linagliptin 5 mg. Empagliflozin 25 mg, linagliptin 5 mg. Excipients: Tablet Core: mannitol, pregelatinized starch, corn starch, copovidone, crospovidone, talc and magnesium stearate. Coating: hypromellose, mannitol, talc, titanium dioxide, polyethylene glycol and ferric oxide, yellow (10 mg/5 mg) or ferric oxide, red (25 mg/5 mg).

Mechanism Of Action: Glyxamed combines 2 antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes: empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor

INDICATIONS: Glyxamed is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease . However, the effectiveness of Glyxamed on reducing the risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease has not been established.

DOSAGE AND ADMINISTRATION Recommended Dosage: The recommended dose of Glyxamed is 10 mg empagliflozin/5 mg linagliptin once daily in the morning, taken with or without food. In patients tolerating Glyxamed, the dose may be increased to 25 mg empagliflozin/5 mg linagliptin once daily. In patients with volume depletion, correcting this condition prior to initiation of Glyxamed is recommended